FDA Approves NULIBRY — Sentynl Therapeutics, Inc.

# FDA Approval Newswire **Sentynl Therapeutics Receives FDA Approval for NULIBRY (Fosdenopterin Hydrobromide), Expanding Treatment Options in Rare Disease Market** The FDA approval of NULIBRY, an intravenous therapy developed by Sentynl Therapeutics, positions the company to capture market share in the rare disease segment and potentially establishes a new revenue stream for the biopharmaceutical firm. The designation of this novel fosdenopterin hydrobromide formulation could drive investor interest in Sentynl